BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maleki A, Meese H, Sahawneh H, Foster CS. Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis. Expert Rev Clin Immunol 2016;12:775-86. [PMID: 26972783 DOI: 10.1586/1744666X.2016.1166052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Muhammad F, Avalos PN, Mursalin MH, Ma JX, Callegan MC, Lee DJ. Kallistatin Attenuates Experimental Autoimmune Uveitis by Inhibiting Activation of T Cells. Front Immunol 2020;11:975. [PMID: 32508841 DOI: 10.3389/fimmu.2020.00975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Lee DJ, Preble J, Lee S, Foster CS, Taylor AW. MC5r and A2Ar Deficiencies During Experimental Autoimmune Uveitis Identifies Distinct T cell Polarization Programs and a Biphasic Regulatory Response. Sci Rep 2016;6:37790. [PMID: 27886238 DOI: 10.1038/srep37790] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
3 Teper SJ. Update on the Management of Uveitic Macular Edema. J Clin Med 2021;10:4133. [PMID: 34575244 DOI: 10.3390/jcm10184133] [Reference Citation Analysis]
4 Muhammad F, Trivett A, Wang D, Lee DJ. Tissue-specific production of MicroRNA-155 inhibits melanocortin 5 receptor-dependent suppressor macrophages to promote experimental autoimmune uveitis. Eur J Immunol 2019;49:2074-82. [PMID: 31177529 DOI: 10.1002/eji.201848073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 Maleki A, Stephenson AP, Hajizadeh F. Topical Interferon Alpha 2b in the Treatment of Refractory Diabetic Macular Edema. J Ophthalmic Vis Res. 2020;15:453-458. [PMID: 33133435 DOI: 10.18502/jovr.v15i4.7785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]